Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 9, 2012, Pages 1024-

  Toyoshima, Mikio ^a,b   Chida, Kingo ^b   Suda, Takafumi ^b   Sato, Masaki ^a  

^a HAMAMATSU ROSAI HOSPITAL   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE EXACERBATION; DRUG SAFETY; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 84860649125     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.185.9.1024     Document Type: Letter

References (4)

1. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372-378.
2. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41:256-264.
3. Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, Mimori T, Akizuki M, Ikeda Y. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997;24:2299-2303. (Pubitemid 28005125)
4. Shidara K, Hoshi D, Inoue E, Yamada T, Nakajima A, Taniguchi A, HaraM, Momohara S, Kamatani N, Yamanaka H. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 2010;20:280-286.